CEBPA Mutation by PCR
Order Name
CEBPA PCR
Test Number: 9616990
Revision Date 01/24/2025
Test Number: 9616990
Revision Date 01/24/2025
| Test Name | Methodology | LOINC Code |
|---|---|---|
|
CEBPA Mutation by PCR
|
Polymerase Chain Reaction |
| SPECIMEN REQUIREMENTS | ||||
|---|---|---|---|---|
| Specimen | Specimen Volume (min) | Specimen Type | Specimen Container | Transport Environment |
| Preferred | 5 mL (3 mL) | Whole Blood | EDTA (Lavender Top) | Room Temperature |
| Alternate 1 | 5 mL (3 mL) | Whole Blood | Sodium Heparin (Green Top / No-Gel) | Room Temperature |
| Alternate 2 | 2 mL (1 mL) | Bone Marrow | EDTA (Lavender Top) | Room Temperature |
| Alternate 3 | 2mL (1mL) | Bone Marrow | Sodium Heparin (Green Top / No-Gel) | Room Temperature |
| Instructions | Specimen: 5mL(3mL) Whole Blood or 2mL (1mL) Bone Marrow Container: Lavender-top (EDTA) tube, green-top (sodium heparin) tube Collection: Indicate date and time of collection on the test request form. Submit specimen at room temperature ASAP, Keep at room temperature! (DO NOT FREEZE). Frozen samples will be rejected. Storage Instructions: Maintain specimen at room temperature. If specimen is to be stored prior to shipment, store at 2°C to 8°C. Cause for Rejection: Specimen does not meet all of the above criteria for sample type, container, minimum volume, collection and storage; unsuitable specimens include but are not limited to: frozen whole blood or marrow; a leaking tube; clotted blood or marrow; a grossly hemolyzed specimen or otherwise visibly degraded; specimen suspected of being contaminated by another specimen; specimen contains specific foreign material. |
|||
| GENERAL INFORMATION | |
|---|---|
| Testing Schedule | Mon- Fri |
| Expected TAT | 12-14 Days from set up. |
| Clinical Use | Determine prognosis in cytogenetically normal acute myelogenous leukemia (CN-AML The CEBPA (CCAAT/enhancer binding protein α) gene encodes a transcription factor important for granulocyte differentiation. CEBPA mutations are found in 6% to 15% of de novo acute myeloid leukemia (AML) and in 15% to 18% of AML with normal karyotypes. CEBPA mutations are associated with favorable prognosis in the absence of associated cytogenetic abnormalities and FLT3 internal duplication (FLT3-ITD). Germline CEBPA mutations are a cause of nonsyndromic, familial AML. |
| Performing Labcorp Test Code | 489170 |
| CPT Code(s) | 81218 |
| Lab Section | Reference Lab |